INTRODUCTION
One of the challenges that all eukaryotic cells face is adapting to periods of nutritional or oxygen deprivation. The strategies utilized to combat such stresses have been remarkably well conserved over long evolutionary periods, and one of the most critical adaptive pathways centers around the AMP-activated protein kinase (AMPK). AMPK is widely expressed and consists of a catalytic a subunit and regulatory b and g subunits. It can be activated by phosphorylation at Thr172 of the catalytic subunit by AMPK kinase, a protein that has so far eluded molecular identification. In addition, the allosteric binding of AMP to AMPK enhances both its activity as well the stability of phosphorylated state (1). AMPK was initially described as an activity that phosphorylates and inactivates HMG-CoA reductase and acetyl-CoA carboxylase, thereby decreasing the rates of cholesterol and fatty acid biosynthesis, respectively (1). Subsequent studies have led to the idea that AMPK acts as an intracellular energy sensor, stimulated by the increased intracellular AMP/ATP ratio when cells are stressed by conditions such as hypoxia/ischemia in the heart and excessive contraction in skeletal muscle. Activated AMPK accelerates ATP-producing pathways, such as fatty acid and glucose oxidation, while reducing ATP consumption, ultimately leading to the preservation or restoration of adequate high energy phosphates (2) .
In recent years, the study of AMPK in mammalian organisms has been directed in part towards the identification of physiological processes in which the enzyme is important, and the search for extracellular factors that regulate its activity. In regard to the former, much attention has centered on the role of AMPK in both the short-and long-term response to exercise (3) (4) (5) .
Perhaps more surprising has been the identification of circulating factors implicated as Leptin stimulates phosphorylation and activation of the a2 subunit of AMPK in skeletal muscle, and this has been invoked as a principal mediator of the hormone's action to stimulate fatty-acid oxidation (6) . Adiponectin promotes phosphorylation and activation of AMPK in both liver and skeletal muscle, and again this has been suggested to account for the stimulatory effect of adiponectin on glucose utilization and fatty-acid oxidation (7, 8) . In addition, the anti-diabetic drugs metformin and the thiazolidinediones appear to activate AMPK in liver and skeletal muscle (9) (10) (11) (12) .
Whereas the importance of AMPK to control lipid metabolism in liver and muscle is well established, its role in regulating lipolysis in adipose tissue has remained controversial. The badrenergic signaling pathway represents a prime regulator of triglyceride breakdown, acting via the accumulation of cAMP and subsequent PKA-dependent phosphorylation of hormonesensitive lipase (HSL). The activity of HSL, the rate-limiting enzyme that catalyzes the hydrolysis of triglyceride to diglyceride and monoglyceride, is regulated by both phosphorylation and translocation to the lipid droplet (13, 14) . PKA phosphorylates HSL at Ser563, Ser659 and Ser660, though the first has long been thought responsible for HSL activation. adipose tissues (16) (17) (18) (19) . Pre-incubation of isolated rat adipocytes with AICAR reduced the response of these cells to the lipolytic agent isoproterenol (20, 21) . These observations led to the hypothesis that AMPK antagonizes lipolysis in adipocytes, presumably to prevent futile cycling and depletion of ATP. However, in 1998, Anthonsen et al demonstrated that, whereas mutating Ser659 and Ser660 abolished the enzymatic activity of HSL, replacing Ser563 by alanine did not reduce activity of the enzyme, questioning the importance of inhibiting modification of this residue (22) . In addition, Moule and Denton (23) reported that isoproterenol stimulated AMPK phosphorylation and kinase activity in isolated rat epididymal fat cells, an observation seemingly at odds with an anti-lipolytic role for AMPK. In order to clarify the role of AMPK in regulating lipolysis in adipose tissue, we utilized 3T3-L1 adipocytes as a model system, measuring AMPK phosphorylation and activity after the treatment with different activators and/or inhibitors of the components along the b-adrenergic signaling pathway. Our data support the idea that badrenergic agents activate AMPK via an intermediary rise in cAMP, and that this serves to enhance the lipolytic rate.
EXPERIMENTAL PROCEDURES
Materials. Sp-cAMPs and glycerokinase were from BIOMOL (Plymouth Meeting, PA) and Roche (Basel, Switzerland), respectively. Isoproterenol and all other reagents were purchased from Sigma (St. Louis, MO). Anti-phospho-AMPK antisera has been described (5), and phospho-AKT and phospho-PKA substrate antibodies were obtained from Cell Signaling (Beverly, MA). SAMS peptide was synthesized by Sigma-Genosys (Stanford, CA).
Cell culture. 3T3-L1 fibroblasts were cultured and differentiated as described (24). 3T3-L1 adipocytes were used for experiments 7-12 days after differentiation. In all experiments except for the glycerol release assays, 3T3-L1 adipocytes were preincubated in DMEM + 1% fatty acid free BSA for 2 hrs before the all the treatments. Western immunoblot analysis. Tagged proteins were detected by Western immunoblots as described previously (5) . 3T3-L1 adipocytes were solubilized in adipocyte lysis buffer containing 50mM Tris (pH7.4), 150mM NaCl, 50mM NaF, 5mM sodium pyrophosphate, 0.5% triton X-100, 1mM EDTA, 1mM EGTA, supplemented with the protease inhibitors or in SDS buffer containing PBS + 0.05% SDS. All the SDS-PAGE gels used were 10% polyacrylamide.
Immunocomplex kinase assay. In vitro immunocomplex assays were performed as described previously (5). Briefly, the pre-clarified cell lysates were incubated with anti-AMPK antibody for an hour and protein A agarose beads for another hour. The beads were washed three times with the 3T3-L1 adipocytes lysis buffer and once with the kinase reaction buffer. SAMS peptide was resolved by Coomassie blue staining after electrophoresis on a 4-12% NuPage precast gels (Invitrogen, Carlsbad, CA). The autoradiograms were quantitated using NIH Image 1.61 software.
Glycerol release assay. The stimulation of adipocytes and measurement of glycerol release was performed as described previously (27) . Prior to assaying glycerol release, adipocytes were incubated in KRP (136mM NaCl, 4.7mM KCl, 10mM NaPO 4 pH7.4, 0.9mM MgSO 4 and 0.9mM CaCl 2 ) + 5% fatty acid free BSA for 3 hrs. The samples were diluted two-fold for the amount of glycerol to be in the linear range of the standard curve. Released glycerol was expressed relative to the cellular protein content.
RESULTS

Isoproterenol and forskolin stimulate AMPK phosphorylation and activation in 3T3-L1 adipocytes
To reevaluate the role of AMPK in the regulation of lipolysis, we first considered the phosphorylation state and activity of the enzyme after exposure of 3T3-L1 adipocytes to agents that raise intracellular cAMP. The b-adrenergic agent isoproterenol increased phosphorylation of AMPK at the critical activating threonine residue, T172, as determined by its immunoreactivity with and antibody specific for the phosphorylated state ( Fig. 1 ). This was blocked by preincubation with the b-adrenergic agent antagonist, propranolol. Treatment of adipocytes with forskolin, which activated adenylyl cyclase independent of the receptor, also increased AMPK phosphorylation (Fig. 1) . As a positive control, we exposed cells to AICAR, a cell permeable AMP analog and AMPK activator, which also induced phosphorylation of AMPK to a comparable degree (Fig. 1) . The effect of isoproterenol on AMPK phosphorylation was dosedependent, characterized by a detectable increase at 1mM and reaching the maximum level at 10mM, where phosphorylation was 4-fold above basal (Fig. 2a,b) . Similarly, forskolin produced phosphorylation of AMPK at 1mM and a maximal response of 7-fold at 10mM (Fig. 2c, d ). As a positive control, all extracts were immunoblotted using an antisera that recognizes the consensus phosphorylation site for protein kinase A. Multiple reactive bands were noted after treatment with isoproterenol or forskolin, and the dose-dependency roughly paralleled that for AMPK T172 phosphorylation (Fig. 2) The phosphorylation of AMPK was detectable 1 min after addition of isoproterenol, and reached maximum by15 min (Fig. 3a, b) . The effect of forskolin was slower, not achieving a maximal T172 phosphorylation till 30 min after addition of drug (Fig. 3c, d ).
Phosphorylation of T172 on the alpha subunit of AMPK generally correlates well with AMPK activity, and appears to the major site of phosphorylation by the activating upstream protein kinase AMPKK (28) . To assess directly the effect isoproterenol or forskolin on the activity of AMPK, an immune complex kinase assay was performed on immunoprecipitates of AMPK prepared from adipocytes treated with drugs. Isoproterenol or forskolin increased AMPK activity of 1.8 and 2.5 fold, respectively, correlating with the increased T172 phosphorylation (Fig. 4) . Insulin reduces AMPK phosphorylation through a PI 3'-kinase-dependent pathway. A major regulator of anabolic metabolism, insulin antagonizes adipocyte lipolysis, in part by reducing intracellular cAMP. This is believed to occur by a PI 3'-kinase and Akt/PKB-dependent phosphorylation and activation of cAMP phosphodiesterase 3B (13, 29, 30) . If isoproterenol and forskolin stimulate AMPK by increasing the level of intracellular cAMP, one might expect that insulin would antagonize the activation of AMPK. To test this idea, we first treated 3T3-L1 adipocytes with forskolin, followed after 20 min by the exposure to insulin, and then measured AMPK phosphorylation after an additional 10 minutes. As predicted, insulin substantially reduced the effect of forskolin on AMPK phosphorylation (Fig. 6a, b) . To test whether this effect of insulin is mediated by PI 3'-kinase, cells were also treated with the PI 3'-kinase inhibitor wortmannin. Pre-incubation of wortmannin completely abolished the effect of insulin to antagonize forskolin-induced AMPK phosphorylation, whereas pre-incubation with wortmannin did not change either basal or forskolin-induced phosphorylation of AMPK (Fig. 6a, b) . The effect of insulin on AMPK phosphorylation is likely to represent a physiological meaningful event mediated by interaction with the insulin receptor, as the decreased phosphorylation of AMPK was evident after treatment with 1nM insulin, and achieved a maximum at 10nM insulin (Fig. 6c, d ). This dose-dependency correlated well with phosphorylation of Akt/PKB, a serine/threonine kinase now recognized as an important mediator of the metabolic actions of insulin (Fig. 6c, d ).
AMPK is required for optimal isoproterenol-induced lipolysis. The major physiological target of increased cAMP in the fat cell is the augmentation of lipolysis, i.e. the breakdown of triglyceride to free fatty acid and glycerol. Though the experiments described above show clearly that cAMP positively regulates AMPK, they leave open the question of the contribution of AMPK to the control of lipolysis. In order to resolve this issue, we infected 3T3-L1 adipocytes with recombinant adenoviruses overexpressing either wild type (AMPK a2WT) or dominant inhibitory mutant (AMPK a2KD) of AMPK a2 subunit. To determine that infection by each of the adenoviruses led to expression of protein at roughly equivalent levels, Western blots were performed using anti-AMPKa antibody (Fig. 7a) . Note that the endogenous proteins were not detected at this exposure, indicating a significant degree of overexpression. In addition, the overexpressed proteins were visualized by immunoreactivity with the Myc tag. These data demonstrate that, under the conditions used, both control and mutant AMPK subunits were expressed at equal levels (Fig. 7a) .
Under basal conditions, the relatively modest rate of glycerol release, a direct measure of (Fig. 7b) .
DISCUSSION
In this study, we investigated the role of AMPK in isoproterenol-induced lipolysis in 3T3-L1 adipocytes. Some contradictory data have existed pertaining to this issue, with most reports indicating that AMPK antagonizes triglyceride breakdown in adipocytes. In contrast, our results show clearly that AMPK activation is required for the maximal increase in lipolysis induced by isoproterenol. Moreover, and perhaps more surprisingly, our study also revealed a novel mechanism by which a rise in cAMP levels can lead to an increase in AMPK activity.
Since AMPK has been suggested to be a "metabolic switch" driving the cellular response to nutritional stress, a fair amount of attention has been focused on understanding its control of lipogenesis and fatty acid oxidation. However, the contribution of AMPK to the regulation of lipolysis has remained controversial, largely due the lack of reagents to specifically reduce AMPK activity, as well as the potential non-specificity of AICAR, the drug generally employed to activate AMPK. We have overcome these problems by relying on adenoviral transduction of cultured 3T3-L1 adipocytes with AMPK mutants specifically recognized to either block or activate the enzyme. AMPK exists as a stable heterotrimer; overexpression of a mutant alpha subunit leads to displacement and degradation of the endogenous wildtype subunit, and the production of a catalytically inactive enzyme complex (5) . Using this reagent we show here that the maximal stimulation of lipolysis by agents that raise cAMP depends on AMPK activity. The 50% reduction of glycerol release in shown Fig. 7 is most likely an underestimate of AMPK's contribution to lipolysis, as it is unlikely that more than 75% of the adipocytes were productively infected with recombinant adenovirus under these conditions. Generation of a constitutively active AMPK variant depended on the identification of a series of spontaneous mutations in the by guest on September 1, 2017 http://www.jbc.org/ Downloaded from non-catalytic gamma subunit, initially in a pig with hypertrophy skeletal muscles and then humans with cardiac conduction disturbances (31) (32) (33) . The activating nature of the mutation has been confirmed in tissue culture lines, though precise mechanism remains unclear (34, 35) .
Active AMPK alone had a minimal effect on glycerol release, which probably only emphasizes the critical role of the canonical cAMP pathway through HSL (Yin and Birnbaum, unpublished observations) (13, 36) .
The traditional view that AMP, creatine phosphate and possibly other metabolites are the sole regulators of AMPK has been challenged by the recent reports that leptin and adiponectin can stimulate the activity of the enzyme (6, 8) . Thus far, there has been little understanding of how these hormones transmit the signal from their plasma membrane receptors to the intracellular AMPK. One of the surprising results in the present studies is that agents that increase cAMP or the nucleotide itself activate AMPK in intact cells. This is consistent with the report of Moule and Denton (23) that isoproterenol increases AMPK phosphorylation and kinase activity. In addition to isoproterenol, other b-adrenergic agents such as forskolin also increased AMPK phosphorylation and kinase activity via an intermediary increase in cAMP, as might be expected if AMPK were required for optimal lipolysis. Enthusiasm about the identification of a novel intracellular messenger capable of leading to the activation AMPK is tempered by uncertainty about the mechanism. T172, the phosphorylation site on AMPK responsible for most of the increase in AMPK activity, is not a consensus PKA phosphorylation site, which suggests that even if PKA regulates AMPK activity through an indirect mechanism, such as phosphorylating AMPKK or another unknown upstream kinase(s), or that the effect of cAMP is independent of PKA. There are now several such downstream signaling pathways recognized, including the Epac-Rap1 pathway, which has been implicated in regulating many critical cellular events, ranging from cell proliferation and cell differentiation, to cell adhesion and morphogenesis (37).
However, to out knowledge, this pathway has not been reported to be active in adipocytes.
The other critical question is how AMPK regulates lipolysis. HSL is the rate-limiting enzyme in this process of lipolysis, and both its activity and subcellular location are regulated by phosphorylation. There are three PKA phosphorylation sites present on the regulatory module of HSL, Ser 563, Ser 659, and Ser 660, the latter two being most important for regulation of activity in vitro (22) . However phosphorylation by PKA alone cannot account for the maximal activity of HSL, as in vitro PKA phosphorylation only causes a 1.5-2 fold increase of HSL lipase activity, while isoproterenol stimulates more than 50 fold increase of fatty acid release in vivo (27, 38) . In conclusion, our study demonstrates that the activity of AMPK is required for the maximal lipolysis induced by isoproterenol, and provides a novel mechanism of how AMPK is activated in 3T3-L1 adipocytes. Our data suggest that upon stimulation by b-adrenergic agents, AMPK is phosphorylated and activated, and this activation contributes to the maximal response of lipolysis, possibly by phosphorylating HSL at Ser 565 and promoting the HSL translocation. 
